Articles from Biointron Biological USA Inc.
RushDATA™ Delivers Wet-Lab Validation for AI-Designed Antibodies from Molence Bio’s Mol-1
Biointron Biological USA Inc. ("Biointron") is proud to have supported Molence Bio's Mol-1 project. Mol-1 matches the performance of the leading closed-source model IsoDDE in antibody-antigen structure prediction and can design functional nanobodies from scratch. To show those designs can become real drug candidates, Biointron ran the developability assays using RushDATA™, our wet-lab validation service for AI-designed antibodies.
By Biointron Biological USA Inc. · Via Business Wire · November 16, 2026
Biointron Launches RushData, an Integrated Platform for AI-Driven Antibody Discovery with 1-Day CHO Expression
Biointron Biological USA Inc. ("Biointron"), a leading contract research organization for antibody discovery, expression, and optimization, has launched RushData. RushData is an integrated service platform designed to support the growing demands of AI- and machine learning-driven antibody discovery for global pharma and biotech organizations.
By Biointron Biological USA Inc. · Via Business Wire · July 24, 2026